BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 29259266)

  • 1. Associations of genetic polymorphisms in pTEN/AKT/mTOR signaling pathway genes with cancer risk: A meta-analysis in Asian population.
    Zhang Z; Chen Q; Zhang J; Wang Y; Hu X; Yin S; He M; Guan S; Qin W; Xiao Q; Zhao H; Yao W; Wu H; Wei M
    Sci Rep; 2017 Dec; 7(1):17844. PubMed ID: 29259266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The genetic variants in the PTEN/PI3K/AKT pathway predict susceptibility and CE(A)F chemotherapy response to breast cancer and clinical outcomes.
    Li X; Zhang R; Liu Z; Li S; Xu H
    Oncotarget; 2017 Mar; 8(12):20252-20265. PubMed ID: 28423632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic variations in a PTEN/AKT/mTOR axis and prostate cancer risk in a Chinese population.
    Chen J; Shao P; Cao Q; Li P; Li J; Cai H; Zhu J; Wang M; Zhang Z; Qin C; Yin C
    PLoS One; 2012; 7(7):e40817. PubMed ID: 22815832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A functional variant in the MTOR promoter modulates its expression and is associated with renal cell cancer risk.
    Cao Q; Ju X; Li P; Meng X; Shao P; Cai H; Wang M; Zhang Z; Qin C; Yin C
    PLoS One; 2012; 7(11):e50302. PubMed ID: 23209702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis of the effect of rs2295080 and rs2536 polymorphisms within the mTOR gene on cancer risk.
    Qi GH; Wang CH; Zhang HG; Yu JG; Ding F; Song ZC; Xia QH
    Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32597485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic polymorphisms of mTOR and cancer risk: a systematic review and updated meta-analysis.
    Zining J; Lu X; Caiyun H; Yuan Y
    Oncotarget; 2016 Aug; 7(35):57464-57480. PubMed ID: 27462867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The associations of hub gene polymorphisms in PI3K/AKT/mTOR pathway and Schistosomiasis Japonica infection and hepatic fibrosis.
    Xiao Q; Yu H; Zhu X
    Infect Genet Evol; 2020 Nov; 85():104423. PubMed ID: 32554084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations between single-nucleotide polymorphisms in the PI3K-PTEN-AKT-mTOR pathway and increased risk of brain metastasis in patients with non-small cell lung cancer.
    Li Q; Yang J; Yu Q; Wu H; Liu B; Xiong H; Hu G; Zhao J; Yuan X; Liao Z
    Clin Cancer Res; 2013 Nov; 19(22):6252-60. PubMed ID: 24077347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles of genetic variants in the PI3K/PTEN pathways in susceptibility to colorectal carcinoma and clinical outcomes treated with FOLFOX regimen.
    Lin L; Zhang Z; Zhang W; Wang L; Wang J
    Int J Clin Exp Pathol; 2015; 8(10):13314-22. PubMed ID: 26722535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1.
    Slattery ML; Herrick JS; Lundgreen A; Fitzpatrick FA; Curtin K; Wolff RK
    Carcinogenesis; 2010 Sep; 31(9):1604-11. PubMed ID: 20622004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.
    Xu JL; Wang ZW; Hu LM; Yin ZQ; Huang MD; Hu ZB; Shen HB; Shu YQ
    Asian Pac J Cancer Prev; 2012; 13(5):2157-62. PubMed ID: 22901187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of mTOR polymorphisms with cancer risk and clinical outcomes: a meta-analysis.
    Shao J; Li Y; Zhao P; Yue X; Jiang J; Liang X; He X
    PLoS One; 2014; 9(5):e97085. PubMed ID: 24816861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy.
    Hildebrandt MA; Yang H; Hung MC; Izzo JG; Huang M; Lin J; Ajani JA; Wu X
    J Clin Oncol; 2009 Feb; 27(6):857-71. PubMed ID: 19164214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of genetic variations in the PI3K/PTEN/AKT/mTOR pathway in Korean patients with colorectal cancer.
    Kim JG; Chae YS; Sohn SK; Kang BW; Moon JH; Lee SJ; Jeon SW; Park JS; Park JY; Choi GS
    Oncology; 2010; 79(3-4):278-82. PubMed ID: 21412012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes.
    Wang LE; Ma H; Hale KS; Yin M; Meyer LA; Liu H; Li J; Lu KH; Hennessy BT; Li X; Spitz MR; Wei Q; Mills GB
    J Cancer Res Clin Oncol; 2012 Mar; 138(3):377-85. PubMed ID: 22146979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the MTOR and AKT1 genes polymorphisms on papillary thyroid cancer development.
    Maruei-Milan R; Saravani M; Heidari Z; Asadi-Tarani M; Salimi S
    IUBMB Life; 2020 Dec; 72(12):2601-2610. PubMed ID: 33107190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Putative functional variants of PI3K/AKT/mTOR pathway are associated with knee osteoarthritis susceptibility.
    Wang K; Chu M; Wang F; Zhao Y; Chen H; Dai X
    J Clin Lab Anal; 2020 Jun; 34(6):e23240. PubMed ID: 32052902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A GG allele of 3'-side AKT1 SNP is associated with decreased AKT1 activation and better prognosis of gastric cancer.
    Wang X; Lin Y; Lan F; Yu Y; Ouyang X; Wang X; Huang Q; Wang L; Tan J; Zheng F
    J Cancer Res Clin Oncol; 2014 Aug; 140(8):1399-411. PubMed ID: 24737346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic variants in mTOR-pathway-related genes contribute to osteoarthritis susceptibility.
    Xu Z; Yang H; Zhou X; Li J; Jiang L; Li D; Wu L; Huang Y; Xu N
    Int Immunopharmacol; 2019 Dec; 77():105960. PubMed ID: 31704287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single nucleotide polymorphisms rs701848 and rs2735343 in PTEN increases cancer risks in an Asian population.
    Song DD; Zhang Q; Li JH; Hao RM; Ma Y; Wang PY; Xie SY
    Oncotarget; 2017 Nov; 8(56):96290-96300. PubMed ID: 29221206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.